Drugs / CU01-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05718375 | Feb 2023 → Nov 2025 | diabetic kidney disease | Curacle Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CU01-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05718375 ↗ |
| Route | Oral | “1 Tab/3 times/day (CU01-1001 120 mg, Breakfast and Dinner; Placebo 120 mg, Lunch)” NCT05718375 ↗ |